Pain is good. Or finding non-opioid ways to manage it is good, if Latigo Biotherapeutics’ $150 million March fundraise is ...

The opioid crisis has claimed the lives of over half a million Americans since the beginning of the epidemic, a process ...

The Value Fund finished Q1 +3.0% net of fees and expenses. Markets had a challenging start to 2025, with elevated volatility across the major indices. The top contributor to the portfolio in Q1 was ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, ...

FDA Approves New-Age NON-OPIOID Pain Relief Formula That Does NOT Shut Down Your Vital Organs Via Heroin Addiction. NEWS ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

The economy has been on shaky ground for a while, and President Trump's tariffs and trade wars could finally send it into a ...

FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve clinical outcomes and QOL.

While the approval of Journavx (suzetrigine) has gained much positivity in non-opioid pain management, former FDA medical officer in the division of psychiatry, Josef Witt-Doerring, M.D., warns that ...